NCT04678648
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: RAS
Breast Cancer Tissue:
Recruitment Status: Recruiting
Phase 1
Drug Category: Tyrosine-Kinase Inhibitor
Key Eligibility Criteria:
Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases:
Additional Notes:
Exclusions: Participants receiving cancer therapy at the time of enrollment.
https://ClinicalTrials.gov/show/NCT04678648